A new study suggests that non-oxidized, biologically active parathyroid hormone (PTH) testing may help determine mortality risk in hemodialysis patients.
John Schieszer reports in today’s Medical Minute that current testing methods for PTH levels may overlook a key element.
Next post in The Medical Minute
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
Want to read more?
Please login or register first to view this content.